(IVVD) Invivyd - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US46187W1071
Stock: Antibodies, Vaccines, Treatments, Infectious Diseases
Total Rating 40
Risk 39
Buy Signal -0.42
| Risk 5d forecast | |
|---|---|
| Volatility | 125% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.07 |
| Alpha | 36.84 |
| Character TTM | |
|---|---|
| Beta | 2.708 |
| Beta Downside | 1.417 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.90% |
| CAGR/Max DD | 0.05 |
Risks
Technicals:
volatile
Description: IVVD Invivyd March 04, 2026
Invivyd, Inc. (IVVD) is a biopharmaceutical company developing antibody-based solutions for infectious diseases, primarily COVID-19. Their pipeline includes PEMGARDA, a monoclonal antibody for COVID-19 prevention, and VYD2311 and Adintrevimab, also for COVID-19. They also have early-stage candidates for influenza and COVID-19 prevention. The biotechnology sector is characterized by lengthy and expensive drug development cycles.
The company focuses on the discovery, development, and commercialization of these antibody treatments. Their business model relies on advancing these drug candidates through clinical trials and regulatory approval. Invivyd collaborates with Adimab, LLC for antibody discovery and optimization. Further research into IVVDs financials and market position can provide a deeper understanding of its investment profile.
Headlines to watch out for
- PEMGARDA sales drive revenue growth
- Clinical trial results impact future drug approvals
- Regulatory decisions on COVID-19 therapies
- Competition from other infectious disease treatments
- Research and development expenses affect profitability
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -59.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.58 > 0.02 and ΔFCF/TA 60.94 > 1.0 |
| NWC/Revenue: 130.4% < 20% (prev 497.4%; Δ -366.9% < -1%) |
| CFO/TA -0.58 > 3% & CFO -80.3m > Net Income -59.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.2m) vs 12m ago 42.41% < -2% |
| Gross Margin: 93.34% > 18% (prev 0.87%; Δ 9.25k % > 0.5%) |
| Asset Turnover: 33.24% > 50% (prev 9.01%; Δ 24.23% > 0%) |
| Interest Coverage Ratio: -33.91 > 6 (EBITDA TTM -58.5m / Interest Expense TTM -1.82m) |
Altman Z'' -15.00
| A: 0.47 (Total Current Assets 109.8m - Total Current Liabilities 44.5m) / Total Assets 139.2m |
| B: -6.78 (Retained Earnings -943.4m / Total Assets 139.2m) |
| C: -0.41 (EBIT TTM -61.7m / Avg Total Assets 150.5m) |
| D: -20.47 (Book Value of Equity -943.4m / Total Liabilities 46.1m) |
| Altman-Z'' Score: -43.27 = D |
Beneish M 0.01
| DSRI: 0.33 (Receivables 9.85m/8.61m, Revenue 50.0m/14.6m) |
| GMI: 0.93 (GM 93.34% / 86.74%) |
| AQI: 3.97 (AQ_t 0.18 / AQ_t-1 0.05) |
| SGI: 3.43 (Revenue 50.0m / 14.6m) |
| TATA: 0.15 (NI -59.9m - CFO -80.3m) / TA 139.2m) |
| Beneish M-Score: 0.01 (Cap -4..+1) = D |
What is the price of IVVD shares?
As of March 12, 2026, the stock is trading at USD 1.83 with a total of 3,309,434 shares traded.
Over the past week, the price has changed by +11.11%, over one month by +18.01%, over three months by -20.17% and over the past year by +124.59%.
Over the past week, the price has changed by +11.11%, over one month by +18.01%, over three months by -20.17% and over the past year by +124.59%.
Is IVVD a buy, sell or hold?
Invivyd has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy IVVD.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IVVD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 446.4% |
| Analysts Target Price | 10 | 446.4% |
IVVD Fundamental Data Overview March 12, 2026
P/E Forward = 18.9394
P/S = 9.8055
P/B = 5.166
Revenue TTM = 50.0m USD
EBIT TTM = -61.7m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 2.68m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -82.3m USD (from netDebt column, last quarter)
Enterprise Value = 399.9m USD (482.2m + Debt 2.68m - CCE 85.0m)
Interest Coverage Ratio = -33.91 (Ebit TTM -61.7m / Interest Expense TTM -1.82m)
EV/FCF = -4.97x (Enterprise Value 399.9m / FCF TTM -80.4m)
FCF Yield = -20.11% (FCF TTM -80.4m / Enterprise Value 399.9m)
FCF Margin = -160.8% (FCF TTM -80.4m / Revenue TTM 50.0m)
Net Margin = -119.6% (Net Income TTM -59.9m / Revenue TTM 50.0m)
Gross Margin = 93.34% ((Revenue TTM 50.0m - Cost of Revenue TTM 3.33m) / Revenue TTM)
Gross Margin QoQ = 91.71% (prev 94.19%)
Tobins Q-Ratio = 2.87 (Enterprise Value 399.9m / Total Assets 139.2m)
Interest Expense / Debt = 140.1% (Interest Expense 3.75m / Debt 2.68m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.7m (EBIT -61.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.47 (Total Current Assets 109.8m / Total Current Liabilities 44.5m)
Debt / Equity = 0.03 (Debt 2.68m / totalStockholderEquity, last quarter 93.1m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -82.3m / EBITDA -58.5m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -82.3m / FCF TTM -80.4m)
Total Stockholder Equity = 64.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.76% (Net Income -59.9m / Total Assets 139.2m)
RoE = -92.97% (Net Income TTM -59.9m / Total Stockholder Equity 64.4m)
RoCE = -91.97% (EBIT -61.7m / Capital Employed (Equity 64.4m + L.T.Debt 2.68m))
RoIC = -75.68% (negative operating profit) (NOPAT -48.7m / Invested Capital 64.4m)
WACC = 15.80% (E(482.2m)/V(484.9m) * Re(15.89%) + (debt cost/tax rate unavailable))
Discount Rate = 15.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.46%
[DCF] Fair Price = unknown (Cash Flow -80.4m)
EPS Correlation: 73.57 | EPS CAGR: 138.7% | SUE: 0.82 | # QB: 0
Revenue Correlation: 87.36 | Revenue CAGR: 87.20% | SUE: 0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.14 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+68.2% | Growth Revenue=+146.6%
P/S = 9.8055
P/B = 5.166
Revenue TTM = 50.0m USD
EBIT TTM = -61.7m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 2.68m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -82.3m USD (from netDebt column, last quarter)
Enterprise Value = 399.9m USD (482.2m + Debt 2.68m - CCE 85.0m)
Interest Coverage Ratio = -33.91 (Ebit TTM -61.7m / Interest Expense TTM -1.82m)
EV/FCF = -4.97x (Enterprise Value 399.9m / FCF TTM -80.4m)
FCF Yield = -20.11% (FCF TTM -80.4m / Enterprise Value 399.9m)
FCF Margin = -160.8% (FCF TTM -80.4m / Revenue TTM 50.0m)
Net Margin = -119.6% (Net Income TTM -59.9m / Revenue TTM 50.0m)
Gross Margin = 93.34% ((Revenue TTM 50.0m - Cost of Revenue TTM 3.33m) / Revenue TTM)
Gross Margin QoQ = 91.71% (prev 94.19%)
Tobins Q-Ratio = 2.87 (Enterprise Value 399.9m / Total Assets 139.2m)
Interest Expense / Debt = 140.1% (Interest Expense 3.75m / Debt 2.68m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.7m (EBIT -61.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.47 (Total Current Assets 109.8m / Total Current Liabilities 44.5m)
Debt / Equity = 0.03 (Debt 2.68m / totalStockholderEquity, last quarter 93.1m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -82.3m / EBITDA -58.5m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -82.3m / FCF TTM -80.4m)
Total Stockholder Equity = 64.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.76% (Net Income -59.9m / Total Assets 139.2m)
RoE = -92.97% (Net Income TTM -59.9m / Total Stockholder Equity 64.4m)
RoCE = -91.97% (EBIT -61.7m / Capital Employed (Equity 64.4m + L.T.Debt 2.68m))
RoIC = -75.68% (negative operating profit) (NOPAT -48.7m / Invested Capital 64.4m)
WACC = 15.80% (E(482.2m)/V(484.9m) * Re(15.89%) + (debt cost/tax rate unavailable))
Discount Rate = 15.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.46%
[DCF] Fair Price = unknown (Cash Flow -80.4m)
EPS Correlation: 73.57 | EPS CAGR: 138.7% | SUE: 0.82 | # QB: 0
Revenue Correlation: 87.36 | Revenue CAGR: 87.20% | SUE: 0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.14 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+68.2% | Growth Revenue=+146.6%